



Disposals of own shares

Brussels (Belgium), 18 June 2021 – 20:00 (CEST) – regulated information

Disposal of own shares

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long Term Incentive Program of the UCB Group, as follows:

Date of transaction	Time	LTI Plan	Number of disposed UCB shares	Price
11 June 2021	12:58:01	Stock Option Plan 2012	100	€ 32,36
11 June 2021	16:16:14	Stock Option Plan 2012	100	€ 32,36
14 June 2021	10:23:03	Stock Option Plan 2012	100	€ 32,36
14 June 2021	17:14:23	Stock Option Plan 2015	497	€ 67,35
15 June 2021	10:06:56	Stock Option Plan 2018	1.087	€ 66,18
15 June 2021	15:54:32	Stock Option Plan 2012	600	€ 32,36
15 June 2021	15:57:47	Stock Option Plan 2013	111	€ 49,80
15 June 2021	16:15:22	Stock Option Plan 2018	518	€ 66,18
16 June 2021	09:00:10	Stock Option Plan 2017	1.231	€ 70,26
16 June 2021	09:00:10	Stock Option Plan 2017	1.553	€ 70,26
16 June 2021	10:29:54	Stock Option Plan 2018	1.821	€ 66,18
16 June 2021	10:41:51	Stock Option Plan 2016	450	€ 67,24
16 June 2021	10:51:54	Stock Option Plan 2012	100	€ 32,36
16 June 2021	13:49:51	Stock Option Plan 2013	100	€ 49,80
17 June 2021	09:00:55	Stock Option Plan 2012	200	€ 32,36
17 June 2021	15:35:00	Stock Option Plan 2018	877	€ 66,18

This press release is available on UCB SA/NV's website via the following [link](#).

Investor Relations

Antje Witte,
Investor Relations, UCB

T +32 2 559 94 14,
antje.witte@ucb.com

Corporate Communications

Laurent Schots
Media Relations, UCB

T+32.2.559.92.64
laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 400 people in nearly 40 countries, the company generated revenue of € 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news